NCT01884961View on ClinicalTrials.gov

Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 9, 2012

Primary Completion Date

June 30, 2021

Study Completion Date

January 31, 2025

Conditions
Metastatic Renal Cell CancerMalignant Melanoma, Metastatic
Interventions
OTHER

Boost of radiotherapy + high dose IL-2 treatment

Boost of radiotherapy + high dose IL-2 treatment

Trial Locations (1)

47014

UO Oncologia Medica, IRCCS IRST, Meldola (FC)

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER

NCT01884961 - Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2 | Biotech Hunter | Biotech Hunter